Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 254

1.

3D-Embedded Cell Cultures to Study Tendon Biology.

Gehwolf R, Spitzer G, Wagner A, Lehner C, Weissenbacher N, Tempfer H, Traweger A.

Methods Mol Biol. 2019 Feb 8. doi: 10.1007/7651_2019_208. [Epub ahead of print]

PMID:
30734212
2.

Sarcoidosis: patient treatment priorities.

Baughman RP, Barriuso R, Beyer K, Boyd J, Hochreiter J, Knoet C, Martone F, Quadder B, Richardson J, Spitzer G, Valeyre D, Ziosi G.

ERJ Open Res. 2018 Dec 21;4(4). pii: 00141-2018. doi: 10.1183/23120541.00141-2018. eCollection 2018 Oct.

3.

Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia.

Baerlocher GM, Oppliger Leibundgut E, Ottmann OG, Spitzer G, Odenike O, McDevitt MA, Röth A, Daskalakis M, Burington B, Stuart M, Snyder DS.

N Engl J Med. 2015 Sep 3;373(10):920-8. doi: 10.1056/NEJMoa1503479.

4.

A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma.

Benson DM Jr, Cohen AD, Jagannath S, Munshi NC, Spitzer G, Hofmeister CC, Efebera YA, Andre P, Zerbib R, Caligiuri MA.

Clin Cancer Res. 2015 Sep 15;21(18):4055-61. doi: 10.1158/1078-0432.CCR-15-0304. Epub 2015 May 21.

5.

Alternative strategy to achieve increased overall survival and better quality of life in patients with second-line advanced non-small-cell lung cancer.

Spitzer G, Socinski MA.

J Clin Oncol. 2015 Feb 10;33(5):522-3. doi: 10.1200/JCO.2014.58.1603. Epub 2015 Jan 12. No abstract available.

PMID:
25584003
6.

Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression.

Jacobsen ED, Sharman JP, Oki Y, Advani RH, Winter JN, Bello CM, Spitzer G, Palanca-Wessels MC, Kennedy DA, Levine P, Yang J, Bartlett NL.

Blood. 2015 Feb 26;125(9):1394-402. doi: 10.1182/blood-2014-09-598763. Epub 2015 Jan 8.

7.

Microcirculation in hypertensive patients.

Jung F, Pindur G, Ohlmann P, Spitzer G, Sternitzky R, Franke RP, Leithäuser B, Wolf S, Park JW.

Biorheology. 2013;50(5-6):241-55. doi: 10.3233/BIR-130645. Review.

PMID:
24398607
8.

Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma.

Matasar MJ, Czuczman MS, Rodriguez MA, Fennessy M, Shea TC, Spitzer G, Lossos IS, Kharfan-Dabaja MA, Joyce R, Fayad L, Henkel K, Liao Q, Edvardsen K, Jewell RC, Fecteau D, Singh RP, Lisby S, Moskowitz CH.

Blood. 2013 Jul 25;122(4):499-506. doi: 10.1182/blood-2012-12-472027. Epub 2013 May 21.

9.

Cleavage entropy as quantitative measure of protease specificity.

Fuchs JE, von Grafenstein S, Huber RG, Margreiter MA, Spitzer GM, Wallnoefer HG, Liedl KR.

PLoS Comput Biol. 2013 Apr;9(4):e1003007. doi: 10.1371/journal.pcbi.1003007. Epub 2013 Apr 18.

10.

Dynamic regulation of phenylalanine hydroxylase by simulated redox manipulation.

Fuchs JE, Huber RG, von Grafenstein S, Wallnoefer HG, Spitzer GM, Fuchs D, Liedl KR.

PLoS One. 2012;7(12):e53005. doi: 10.1371/journal.pone.0053005. Epub 2012 Dec 31.

11.

Qualitative prediction of blood-brain barrier permeability on a large and refined dataset.

Muehlbacher M, Spitzer GM, Liedl KR, Kornhuber J.

J Comput Aided Mol Des. 2011 Dec;25(12):1095-106. doi: 10.1007/s10822-011-9478-1. Epub 2011 Nov 23.

12.

Identification of novel functional inhibitors of acid sphingomyelinase.

Kornhuber J, Muehlbacher M, Trapp S, Pechmann S, Friedl A, Reichel M, Mühle C, Terfloth L, Groemer TW, Spitzer GM, Liedl KR, Gulbins E, Tripal P.

PLoS One. 2011;6(8):e23852. doi: 10.1371/journal.pone.0023852. Epub 2011 Aug 31.

13.

Minor groove binders and drugs targeting proteins cover complementary regions in chemical shape space.

Fuchs JE, Spitzer GM, Javed A, Biela A, Kreutz C, Wellenzohn B, Liedl KR.

J Chem Inf Model. 2011 Sep 26;51(9):2223-32. doi: 10.1021/ci200237c. Epub 2011 Aug 26.

PMID:
21819135
14.

Development of anti-viral agents using molecular modeling and virtual screening techniques.

Kirchmair J, Distinto S, Liedl KR, Markt P, Rollinger JM, Schuster D, Spitzer GM, Wolber G.

Infect Disord Drug Targets. 2011 Feb;11(1):64-93. Review.

PMID:
21303343
15.

One concept, three implementations of 3D pharmacophore-based virtual screening: distinct coverage of chemical search space.

Spitzer GM, Heiss M, Mangold M, Markt P, Kirchmair J, Wolber G, Liedl KR.

J Chem Inf Model. 2010 Jul 26;50(7):1241-7. doi: 10.1021/ci100136b.

PMID:
20583761
16.

Pegfilgrastim appears equivalent to daily dosing of filgrastim to treat neutropenia after autologous peripheral blood stem cell transplantation in patients with non-Hodgkin lymphoma.

Rifkin R, Spitzer G, Orloff G, Mandanas R, McGaughey D, Zhan F, Boehm KA, Asmar L, Beveridge R.

Clin Lymphoma Myeloma Leuk. 2010 Jun;10(3):186-91. doi: 10.3816/CLML.2010.n.029.

PMID:
20511163
17.

Randomized double-blind phase II trial comparing gemcitabine plus LY293111 versus gemcitabine plus placebo in advanced adenocarcinoma of the pancreas.

Saif MW, Oettle H, Vervenne WL, Thomas JP, Spitzer G, Visseren-Grul C, Enas N, Richards DA.

Cancer J. 2009 Jul-Aug;15(4):339-43. doi: 10.1097/PPO.0b013e3181b36264.

PMID:
19672152
18.

How to optimize shape-based virtual screening: choosing the right query and including chemical information.

Kirchmair J, Distinto S, Markt P, Schuster D, Spitzer GM, Liedl KR, Wolber G.

J Chem Inf Model. 2009 Mar;49(3):678-92. doi: 10.1021/ci8004226.

PMID:
19434901
19.

Hydrogen-bonding patterns of minor groove-binder-DNA complexes reveal criteria for discovery of new scaffolds.

Spitzer GM, Wellenzohn B, Markt P, Kirchmair J, Langer T, Liedl KR.

J Chem Inf Model. 2009 Apr;49(4):1063-9. doi: 10.1021/ci800455f.

PMID:
19275189
20.

Discovery of novel CB2 receptor ligands by a pharmacophore-based virtual screening workflow.

Markt P, Feldmann C, Rollinger JM, Raduner S, Schuster D, Kirchmair J, Distinto S, Spitzer GM, Wolber G, Laggner C, Altmann KH, Langer T, Gertsch J.

J Med Chem. 2009 Jan 22;52(2):369-78. doi: 10.1021/jm801044g.

PMID:
19143566
21.

Sequence-specific positions of water molecules at the interface between DNA and minor groove binders.

Spitzer GM, Fuchs JE, Markt P, Kirchmair J, Wellenzohn B, Langer T, Liedl KR.

Chemphyschem. 2008 Dec 22;9(18):2766-71. doi: 10.1002/cphc.200800647.

PMID:
19025733
22.

The Protein Data Bank (PDB), its related services and software tools as key components for in silico guided drug discovery.

Kirchmair J, Markt P, Distinto S, Schuster D, Spitzer GM, Liedl KR, Langer T, Wolber G.

J Med Chem. 2008 Nov 27;51(22):7021-40. doi: 10.1021/jm8005977. No abstract available.

PMID:
18975926
23.

Discovery of novel PPAR ligands by a virtual screening approach based on pharmacophore modeling, 3D shape, and electrostatic similarity screening.

Markt P, Petersen RK, Flindt EN, Kristiansen K, Kirchmair J, Spitzer G, Distinto S, Schuster D, Wolber G, Laggner C, Langer T.

J Med Chem. 2008 Oct 23;51(20):6303-17. doi: 10.1021/jm800128k. Epub 2008 Sep 27.

PMID:
18821746
24.

Enhancing drug discovery through in silico screening: strategies to increase true positives retrieval rates.

Kirchmair J, Distinto S, Schuster D, Spitzer G, Langer T, Wolber G.

Curr Med Chem. 2008;15(20):2040-53. Review.

PMID:
18691055
25.

Discovery of novel cathepsin S inhibitors by pharmacophore-based virtual high-throughput screening.

Markt P, McGoohan C, Walker B, Kirchmair J, Feldmann C, De Martino G, Spitzer G, Distinto S, Schuster D, Wolber G, Laggner C, Langer T.

J Chem Inf Model. 2008 Aug;48(8):1693-705. doi: 10.1021/ci800101j. Epub 2008 Jul 19.

PMID:
18637674
26.

DNA minor groove pharmacophores describing sequence specific properties.

Spitzer GM, Wellenzohn B, Laggner C, Langer T, Liedl KR.

J Chem Inf Model. 2007 Jul-Aug;47(4):1580-9. Epub 2007 May 23.

PMID:
17518460
27.

Antidepressant-induced neurogenesis in the hippocampus of adult nonhuman primates.

Perera TD, Coplan JD, Lisanby SH, Lipira CM, Arif M, Carpio C, Spitzer G, Santarelli L, Scharf B, Hen R, Rosoklija G, Sackeim HA, Dwork AJ.

J Neurosci. 2007 May 2;27(18):4894-901.

28.

Plasma cell disorders: myeloma and related conditions. Diagnosis and management.

Spitzer G.

J S C Med Assoc. 2003 Apr;99(4):88-93. Review. No abstract available.

PMID:
12762155
29.

High-dose versus standard chemotherapy in metastatic breast cancer: comparison of Cancer and Leukemia Group B trials with data from the Autologous Blood and Marrow Transplant Registry.

Berry DA, Broadwater G, Klein JP, Antman K, Aisner J, Bitran J, Costanza M, Freytes CO, Stadtmauer E, Gale RP, Henderson IC, Lazarus HM, McCarthy PL Jr, Norton L, Parnes H, Pecora A, Perry MC, Rowlings P, Spitzer G, Horowitz MM.

J Clin Oncol. 2002 Feb 1;20(3):743-50.

PMID:
11821456
30.

Delphi-panel analysis of appropriateness of high-dose chemotherapy and blood cell or bone marrow autotransplants in women with breast cancer.

Gale RP, Park RE, Dubois R, Bitran JD, Buzdar A, Hortobagyi G, Jones SE, Lazar GS, Spitzer G, Swain SM, Vaughn CB, Vogel CE, Martino S.

Clin Transplant. 2000 Feb;14(1):32-41.

PMID:
10693633
31.

Factors correlated with progression-free survival after high-dose chemotherapy and hematopoietic stem cell transplantation for metastatic breast cancer.

Rowlings PA, Williams SF, Antman KH, Fields KK, Fay JW, Reed E, Pelz CJ, Klein JP, Sobocinski KA, Kennedy MJ, Freytes CO, McCarthy PL Jr, Herzig RH, Stadtmauer EA, Lazarus HM, Pecora AL, Bitran JD, Wolff SN, Gale RP, Armitage JO, Vaughan WP, Spitzer G, Horowitz MM.

JAMA. 1999 Oct 13;282(14):1335-43.

PMID:
10527180
32.

Effects of allogeneic peripheral stem cell transplantation in a patient with job syndrome of hyperimmunoglobulinemia E and recurrent infections.

Nester TA, Wagnon AH, Reilly WF, Spitzer G, Kjeldsberg CR, Hill HR.

Am J Med. 1998 Aug;105(2):162-4. No abstract available.

PMID:
9727824
33.

Hydroxyethylstarch sedimentation by gravity ex vivo for red cell reduction of granulocyte apheresis components.

Adkins D, Johnston M, Walsh J, Spitzer G, Goodnough T.

J Clin Apher. 1998;13(2):56-61.

PMID:
9704606
34.

Autologous CD34-selected blood progenitor cell transplants for patients with advanced multiple myeloma.

Schiller G, Vescio R, Freytes C, Spitzer G, Lee M, Wu CH, Cao J, Lee JC, Lichtenstein A, Lill M, Berenson R, Berenson J.

Bone Marrow Transplant. 1998 Jan;21(2):141-5.

35.

Randomized comparison of G-CSF + GM-CSF vs G-CSF alone for mobilization of peripheral blood stem cells: effects on hematopoietic recovery after high-dose chemotherapy.

Spitzer G, Adkins D, Mathews M, Velasquez W, Bowers C, Dunphy F, Kronmueller N, Niemeyer R, McIntyre W, Petruska P.

Bone Marrow Transplant. 1997 Dec;20(11):921-30.

36.
38.

High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America.

Antman KH, Rowlings PA, Vaughan WP, Pelz CJ, Fay JW, Fields KK, Freytes CO, Gale RP, Hillner BE, Holland HK, Kennedy MJ, Klein JP, Lazarus HM, McCarthy PL Jr, Saez R, Spitzer G, Stadtmauer EA, Williams SF, Wolff S, Sobocinski KA, Armitage JO, Horowitz MM.

J Clin Oncol. 1997 May;15(5):1870-9.

PMID:
9164197
39.

Indium-labeled white blood cells apheresed from donors receiving G-CSF localize to sites of inflammation when infused into allogeneic bone marrow transplant recipients.

Adkins D, Goodgold H, Hendershott L, Johnston M, Cravens D, Spitzer G.

Bone Marrow Transplant. 1997 Apr;19(8):809-12.

40.

Antifungal effects of yeast-derived rhu-GM-CSF in patients receiving high-dose chemotherapy given with or without autologous stem cell transplantation: a retrospective analysis.

Peters BG, Adkins DR, Harrison BR, Velasquez WS, Dunphy FR, Petruska PJ, Bowers CE, Niemeyer R, McIntyre W, Vrahnos D, Auberry SE, Spitzer G.

Bone Marrow Transplant. 1996 Jul;18(1):93-102. Review.

PMID:
8832001
41.

Transplantation of CD34+ peripheral blood progenitor cells after high-dose chemotherapy for patients with advanced multiple myeloma.

Schiller G, Vescio R, Freytes C, Spitzer G, Sahebi F, Lee M, Wu CH, Cao J, Lee JC, Hong CH, et al.

Blood. 1995 Jul 1;86(1):390-7.

42.

Allogeneic bone marrow transplantation for leukemia following piperazinedione and fractionated total body irradiation.

Dimopoulos MA, Yau JC, Huan SD, Jagannath S, Spitzer G, Spinolo JA, Zagars GK, LeMaistre CF, Dicke KA, Zander AR.

Am J Hematol. 1994 Jun;46(2):82-6.

PMID:
8172200
43.

Factors predicting long-term survival for metastatic breast cancer patients treated with high-dose chemotherapy and bone marrow support.

Dunphy FR, Spitzer G, Fornoff JE, Yau JC, Huan SD, Dicke KA, Buzdar AU, Hortobagyi GN.

Cancer. 1994 Apr 15;73(8):2157-67. Erratum in: Cancer 1994 Jul 15;74(2):773.

PMID:
8156520
44.

Randomized study of growth factors post-peripheral-blood stem-cell transplant: neutrophil recovery is improved with modest clinical benefit.

Spitzer G, Adkins DR, Spencer V, Dunphy FR, Petruska PJ, Velasquez WS, Bowers CE, Kronmueller N, Niemeyer R, McIntyre W.

J Clin Oncol. 1994 Apr;12(4):661-70.

PMID:
7512124
45.

High-dose therapy with stem cell support in solid tumors.

Spitzer G, Dunphy FR, Bowers CE, Adkins DR.

Med Oncol. 1994;11(2):53-62. Review.

PMID:
7850264
46.

Irreversible, severe congestive cardiomyopathy occurring in association with interferon alpha therapy.

Zimmerman S, Adkins D, Graham M, Petruska P, Bowers C, Vrahnos D, Spitzer G.

Cancer Biother. 1994 Winter;9(4):291-9.

PMID:
7719376
47.
48.

Dose escalation of mitoxantrone given with thiotepa and autologous bone marrow transplantation for metastatic breast cancer.

Bowers C, Adkins D, Dunphy F, Harrison B, LeMaistre CF, Spitzer G.

Bone Marrow Transplant. 1993 Nov;12(5):525-30.

PMID:
8298564
49.

High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin's disease: long-term follow-up in 128 patients.

Bierman PJ, Bagin RG, Jagannath S, Vose JM, Spitzer G, Kessinger A, Dicke KA, Armitage JO.

Ann Oncol. 1993 Nov;4(9):767-73.

PMID:
8280658
50.

Cisplatin-CBV with autologous bone marrow transplantation for relapsed Hodgkin's disease.

Spinolo JA, Jagannath S, Velásquez W, Spitzer G, Cabanillas F, Hagemeister F, Horwitz LJ, Dicke KA.

Leuk Lymphoma. 1993 Jan;9(1-2):71-7.

PMID:
8477204

Supplemental Content

Loading ...
Support Center